Pyruvate dehydrogenase inactivity is not responsible for sepsis-induced insulin resistance
- 1 April 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 24 (4) , 566-574
- https://doi.org/10.1097/00003246-199604000-00004
Abstract
To determine whether activation of pyruvate dehydrogenase with dichloroacetate can reverse sepsis-induced insulin resistance in humans or rats. Prospective, controlled study. Intensive care unit (ICU) and laboratory at a university medical center. Nine patients were admitted to the ICU with Gram-negative sepsis, confirmed by cultures. In addition, chronically instrumented, Sprague-Dawley rats, either controls or with live Escherichia coli-induced sepsis. Hyperinsulinemic euglycemic clamp, with or without coadministration of dichloroacetate. In humans, a primed, constant infusion of [6,6-2H2]glucose was used to determine endogenous glucose production and whole-body glucose disposal. Septic humans exhibited impaired maximal insulin-stimulated glucose utilization (39.5 +/- 2.7 mumol/kg/min), despite complete suppression of endogenous glucose production. In rats, a primed, constant infusion of [3-3H]glucose was used to determine endogenous glucose production and whole-body glucose disposal. Tissue glucose uptake in vivo was determined by [14C]-2-deoxyglucose uptake. Maximal, whole-body, insulin-stimulated glucose utilization was 205 +/- 11 and 146 +/- 9 mumol/kg/min in control and septic rats, respectively. The defect was specific to skeletal muscle and heart. Stimulation of pyruvate dehydrogenase with dichloroacetate caused a 50% decrease in plasma lactate concentration but failed to improve whole-body insulin-stimulated glucose utilization in either the septic human or rat. Dichloroacetate reversed the impairment of insulin-stimulated myocardial glucose uptake in septic rats, but did not influence skeletal muscle glucose uptake either under basal conditions or during insulin stimulation. Activation of pyruvate dehydrogenase with dichloroacetate does not ameliorate the impairment of whole-body, insulin-stimulated glucose uptake in septic humans or rats, or reverse the specific defect in insulin-mediated skeletal muscle glucose uptake by septic rats. Therefore, the decreased pyruvate dehydrogenase activity associated with sepsis does not appear to mediate sepsis-induced insulin resistance during insulin-stimulated glucose uptake at either the whole-body or tissue level.Keywords
This publication has 19 references indexed in Scilit:
- Gram-Negative Infection Increases Noninsulin-Mediated Glucose Disposal*Endocrinology, 1991
- Molecular biology and biochemistry of pyruvate dehydrogenase complexes 1The FASEB Journal, 1990
- Insulin-mediated glucose uptake by individual tissues during sepsisMetabolism, 1990
- Differentiation between septic and postburn insulin resistanceMetabolism, 1989
- Regulation of Glucose Metabolism by Altered Pyruvate Dehydrogenase Activity. I. Potential Site of Insulin Resistance in SepsisJournal of Parenteral and Enteral Nutrition, 1986
- APACHE IICritical Care Medicine, 1985
- The grading of sepsisBritish Journal of Surgery, 1983
- Septic AutocannibalismAnnals of Surgery, 1980
- Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humansDiabetologia, 1980
- Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acidsBiochemical Journal, 1974